凯利泰(300326) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was CNY 246.21 million, a decrease of 16.37% compared to CNY 294.40 million in the same period last year[6]. - Net profit attributable to shareholders was CNY 10.88 million, down 85.48% from CNY 74.90 million year-on-year[6]. - The basic earnings per share decreased to CNY 0.0152, down 85.48% from CNY 0.1045 in the same period last year[6]. - Net profit for Q1 2024 was CNY 16.55 million, a decline of 78.0% from CNY 75.08 million in Q1 2023[29]. - The company reported a significant drop in investment income, recording a loss of CNY 2.45 million compared to a gain of CNY 29.19 million in the same period last year[29]. Cash Flow - The net cash flow from operating activities was negative CNY 19.50 million, a decline of 125.48% compared to CNY 76.51 million in the previous year[6]. - The net cash flow from operating activities for the current period is -19.50 million, a decrease of 9.60 million or 125.48% compared to the same period last year, primarily due to reduced revenue in the orthopedic manufacturing and trading segments[19]. - The net cash flow from investment activities is -24.39 million, a decrease of 17.28 million or 243.03% year-over-year, attributed to increased investment payments and net cash outflow from bank wealth management[20]. - The net cash flow from financing activities is 0.93 million, an increase of 6.05 million or 118.21% compared to the previous year, mainly due to an increase in net bank borrowings and reduced interest expenses[20]. - The company’s cash flow from operating activities showed a decline, reflecting challenges in revenue generation[28]. - The net cash flow from operating activities was -19,497,653.07 yuan, a significant decrease compared to 76,514,802.08 yuan in the previous period, indicating a decline in operational performance[31]. Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 3.35 billion, a slight decrease of 0.12% from CNY 3.35 billion at the end of the previous year[6]. - The total assets as of the end of Q1 2024 were CNY 3.35 billion, slightly down from CNY 3.35 billion at the end of Q4 2023[26]. - Total liabilities decreased to CNY 383.62 million from CNY 405.35 million in the previous quarter[26]. Operational Challenges - The implementation of the national volume-based procurement policy significantly impacted the sales prices of orthopedic products, leading to a substantial decline in revenue and profit[9]. - The company expects continued challenges in the orthopedic segment due to the ongoing effects of the procurement policy[9]. - The company reported a significant decrease in financial expenses due to lower financing costs compared to the previous year[19]. - Other income decreased due to a reduction in government subsidies recognized during the reporting period[19]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 50,022[22]. - The largest shareholder, Yongjin Investment Holdings, holds 6.99% of the shares, totaling 50,100,000 shares[22]. Investment and Expenditures - The company's investment in non-current assets increased by CNY 1.40 million, reflecting ongoing investments in medical technology[14]. - Research and development expenses increased to CNY 14.98 million, up from CNY 13.02 million in the previous year, indicating a focus on innovation[28]. - The cash paid for purchasing fixed assets and intangible assets was 12,919,004.65 yuan, up from 7,757,749.26 yuan, indicating increased capital expenditures[33]. - The company paid 25,000,000.00 yuan to repay debts, a decrease from 69,129,870.12 yuan in the previous period, suggesting a reduction in debt repayment obligations[33]. Liquidity - Cash and cash equivalents decreased by CNY 25.38 million, primarily due to the use of funds for purchasing bank wealth management products[12]. - The company's cash and cash equivalents decreased from 620.44 million to 366.59 million, reflecting a significant reduction in liquidity[24]. - The total cash and cash equivalents at the end of the period decreased to 361,137,590.27 yuan from 654,769,877.61 yuan, reflecting a significant reduction in liquidity[33]. - The impact of exchange rate changes on cash and cash equivalents was 186,019.31 yuan, contrasting with -2,103,212.22 yuan in the previous period, indicating a positive effect from currency fluctuations[33].